AH Equity Partners Bio II, L.L.C. sold NAUT

June 2, 2026 · Form 4 insider transaction

AH Equity Partners Bio II, L.L.C. sold 384,026 shares of Nautilus Biotechnology, Inc. at $2.35 per share, a transaction worth $902.5K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 2 days after the transaction.

Direction
Disposed (sell-side)
Shares
384,026
Price
$2.35
Total value
$902.5K
Role10% owner
SecurityCommon Stock
Transaction codeS: Open-market sale
Transaction dateJune 2, 2026
Filing dateJune 4, 2026
Shares owned after971,885
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

The reported securities are held by Andreessen Horowitz LSV Fund II, L.P. ("AH LSV Fund II"), for itself and as nominee for Andreessen Horowitz LSV Fund II-B, L.P. and Andreessen Horowitz LSV Fund II-Q, L.P. AH Equity Partners LSV II, L.L.C. ("AH EP LSV II") is the general partner of AH LSV Fund II and has sole voting and dispositive power with regard to the securities held by AH LSV Fund II for itself and as nominee. The managing members of AH EP LSV II are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH LSV Fund II for itself and as nominee.; Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held by AH LSV Fund II for itself and as nominee (and this report shall not be deemed an admission that any such person is the beneficial owner of such securities), except to the extent of such person's pecuniary interest therein, if any.

View the original Form 4 on SEC EDGAR